Amyotrophic Lateral Sclerosis (ALS)

What is Amyotrophic Lateral Sclerosis?

Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig’s disease or motor neuron disease, is a progressive neurodegenerative disorder that affects nerve cells (motor neurons) in the brain and spinal cord. The disease causes muscle weakness, paralysis, and eventually death due to respiratory failure. ALS is classified as a rare disease (Orphanet code: ORPHA:803), affecting approximately 2-3 people per 100,000 worldwide. While ALS can affect anyone, it most commonly develops between ages 40-70, with men slightly more affected than women.

Key statistics

Symptoms

**Early symptoms include:** muscle weakness, muscle twitching (fasciculations), cramping, slurred speech, difficulty swallowing, hand weakness, foot drop.

**Detailed symptom progression:**

**Early signs** often begin subtly with muscle weakness in hands, arms, legs, or muscles controlling speech and swallowing. Patients may notice difficulty buttoning clothes, dropping objects, or tripping frequently. Muscle cramps and fasciculations (visible muscle twitches) are common early indicators.

Submit Your Paper

**Progressive symptoms** include increasing muscle weakness and atrophy, spreading from initial sites to other muscle groups. Speech becomes increasingly slurred (dysarthria), swallowing becomes difficult (dysphagia), and breathing may become labored. Despite severe physical disability, cognitive function typically remains intact in most patients.

**Advanced symptoms** involve severe weakness progressing to paralysis, complete loss of speech, inability to swallow requiring feeding tubes, and respiratory failure requiring mechanical ventilation. The progression is typically asymmetric, meaning one side of the body may be more affected than the other.

Causes and risk factors

ALS occurs in two main forms: sporadic (90-95% of cases) and familial (5-10% of cases). **Sporadic ALS** has no clear genetic cause, though research suggests a combination of genetic susceptibility and environmental factors. **Familial ALS** is inherited and linked to mutations in genes including SOD1, C9orf72, TARDBP, and FUS.

**Risk factors** include advancing age (peak incidence 55-75 years), male gender, family history of ALS or frontotemporal dementia, military service, certain occupational exposures, and possibly smoking. Some studies suggest associations with head trauma, intense physical activity, and exposure to heavy metals or pesticides, though evidence remains inconclusive.

The inheritance pattern for familial ALS is typically autosomal dominant, meaning each child of an affected parent has a 50% chance of inheriting the mutation. However, not all mutation carriers develop the disease due to incomplete penetrance.

Prevention

Currently, there is no known way to prevent ALS. However, early detection through genetic screening and carrier testing can help families make informed decisions. For families with known ALS-causing mutations, genetic counseling is crucial for understanding inheritance risks and reproductive options. While lifestyle modifications cannot prevent ALS, maintaining overall neurological health through regular exercise, avoiding smoking, and minimizing exposure to potential toxins may be beneficial. Early diagnosis is crucial for optimal management and access to emerging treatments.

Complications

Without proper management, ALS leads to severe complications including respiratory failure, malnutrition due to swallowing difficulties, aspiration pneumonia, deep vein thrombosis from immobility, pressure sores, depression and anxiety, and social isolation. **Respiratory failure** is the most common cause of death, typically occurring 2-5 years after symptom onset. **Dysphagia** can lead to choking, dehydration, and aspiration pneumonia. Progressive immobility increases risks of blood clots, infections, and skin breakdown. The psychological impact of progressive disability significantly affects quality of life for patients and families.

Diagnosis

ALS diagnosis relies primarily on clinical criteria, as there is no single definitive test. **The revised El Escorial criteria** assess upper and lower motor neuron signs across four body regions. **Electromyography (EMG)** and nerve conduction studies demonstrate lower motor neuron dysfunction and rule out other conditions. **Magnetic resonance imaging (MRI)** of the brain and spine excludes structural abnormalities that could mimic ALS.

**Laboratory tests** include blood work to rule out other conditions, cerebrospinal fluid analysis if indicated, and **genetic testing** for known ALS genes, particularly in familial cases or younger patients. **Muscle biopsy** is rarely needed but may be performed in atypical cases. The diagnostic process often takes 6-12 months, as physicians must rule out treatable conditions that can mimic ALS.

Treatment

Treatment focuses on slowing disease progression and managing symptoms. **Disease-modifying medications** include riluzole, which may extend survival by 2-3 months, and edaravone, an antioxidant that may slow functional decline in certain patients. Recently, tofersen was approved for patients with SOD1 mutations.

**Supportive care** involves multidisciplinary teams including neurologists, pulmonologists, gastroenterologists, physical therapists, occupational therapists, speech-language pathologists, and nutritionists. **Respiratory support** progresses from non-invasive positive pressure ventilation to tracheostomy and mechanical ventilation. **Nutritional support** may require percutaneous endoscopic gastrostomy (PEG) tube placement.

**Symptomatic treatments** address muscle cramps with quinine or baclofen, excessive saliva with anticholinergic medications, and emotional lability with dextromethorphan-quinidine. Physical and occupational therapy help maintain function and provide assistive devices.

Prognosis

ALS prognosis varies significantly among patients. **Median survival** is 2-5 years from symptom onset, though 10-20% of patients survive more than 10 years. **Bulbar-onset ALS** (affecting speech and swallowing first) typically progresses faster than limb-onset disease. **Younger age at onset** and certain genetic variants may be associated with longer survival.

**Factors influencing prognosis** include site of symptom onset, rate of progression, respiratory function, nutritional status, and access to comprehensive care. Quality of life can remain meaningful with appropriate support, though the disease’s progressive nature presents significant challenges for patients and families.

Quality of life

Living with ALS requires significant lifestyle adaptations and strong support systems. **Home modifications** include wheelchair accessibility, bathroom safety equipment, and communication devices as speech declines. **Nutritional management** focuses on maintaining weight and preventing aspiration, often requiring texture modifications and eventually feeding tubes.

**Exercise** should be moderate to avoid overexertion while maintaining strength and flexibility. **Mental health support** is crucial, as depression and anxiety are common. **Communication aids** range from simple alphabet boards to sophisticated eye-tracking devices for computer access.

**Social connections** remain vital, with many patients finding support through ALS associations and online communities. **Advance care planning** helps ensure patient wishes are respected regarding life-sustaining treatments. **Workplace accommodations** may extend employment duration, while disability benefits provide financial support.

Pregnancy and fertility

ALS rarely affects women of reproductive age, but pregnancy considerations are important for familial cases. **Fertility** is generally not directly affected by ALS. **Pregnancy management** requires careful monitoring by maternal-fetal medicine specialists, particularly for respiratory function and nutritional status.

**Genetic counseling** is essential for women with familial ALS or partners of affected individuals, as each child has a 50% risk of inheriting disease-causing mutations. **Preimplantation genetic diagnosis** may be an option for families with known mutations. Medication safety during pregnancy varies, with riluzole generally avoided due to limited safety data.

Children

Juvenile ALS is extremely rare, representing less than 5% of all cases. **Pediatric presentation** may differ from adult disease, sometimes progressing more slowly. **Genetic testing** is particularly important in young patients, as several genes cause juvenile-onset disease with distinct inheritance patterns.

**School accommodations** may be necessary as the disease progresses, including assistive technology, modified physical education, and eventually homebound instruction. **Transition planning** to adult care requires coordination between pediatric and adult teams. **Family support** is crucial, as childhood ALS affects the entire family unit significantly.

When to see a doctor

**Seek immediate medical attention** for sudden onset of breathing difficulties, severe choking episodes, or signs of aspiration pneumonia including fever and productive cough. **Urgent evaluation** is needed for progressive weakness, persistent muscle twitching, slurred speech, or difficulty swallowing.

**Routine follow-up** should address respiratory function changes, nutritional concerns, equipment needs, and medication adjustments. **Red flag symptoms** requiring immediate attention include respiratory distress, inability to clear secretions, significant weight loss, or severe depression with suicidal thoughts.

Regional context

Limited data exists on ALS prevalence in the Caucasus region specifically. Some studies suggest geographic clustering of ALS in certain populations, potentially related to genetic founder effects or environmental factors. **Healthcare access** for ALS management may be limited in some areas, making telemedicine and regional specialist networks important.

GMJ welcomes contributions from regional researchers to build the evidence base for ALS in the Caucasus, particularly regarding genetic variants, environmental factors, and healthcare delivery models specific to the region.

Research and clinical trials

**Current research** focuses on gene therapy, stem cell treatments, immunotherapy, and neuroprotective agents. **Promising approaches** include antisense oligonucleotides for specific genetic subtypes, combination therapies targeting multiple disease pathways, and biomarker development for earlier diagnosis and treatment monitoring.

**Clinical trials** are ongoing for various therapeutic strategies. Patients and families should consult ClinicalTrials.gov to identify relevant studies. **Biobanking initiatives** collect tissue and data samples to accelerate research progress. Recent advances in understanding ALS genetics and pathophysiology offer hope for more effective treatments.

Frequently asked questions

Is ALS always fatal?

Yes, ALS is currently considered a terminal disease. However, survival varies greatly among patients, with some living many years beyond initial prognosis, particularly with comprehensive supportive care.

Can ALS be inherited?

About 5-10% of ALS cases are familial (inherited), while 90-95% are sporadic with no clear genetic cause. Genetic testing can identify known disease-causing mutations in familial cases.

Does ALS affect cognitive function?

Most ALS patients maintain normal cognitive function, though about 15% develop frontotemporal dementia. Mild cognitive changes may occur in some patients but typically don’t significantly impact daily functioning.

What is the difference between ALS and multiple sclerosis?

ALS affects motor neurons exclusively and is progressive and fatal, while multiple sclerosis affects various nervous system parts, follows a relapsing-remitting pattern in many cases, and is not typically fatal.

Can lifestyle changes slow ALS progression?

While lifestyle changes cannot cure ALS, maintaining good nutrition, appropriate exercise, respiratory care, and comprehensive medical management may help optimize quality of life and potentially extend survival.

Support and resources

**International organizations:**
– ALS Association (alsa.org)
– Motor Neurone Disease Association – UK (mndassociation.org)
– International Alliance of ALS/MND Associations (alsmndalliance.org)
– Orphanet (orpha.net)
– EURORDIS (eurordis.org)
– World Health Organization Neurological Disorders (who.int)

**Research organizations:**
– ALS Therapy Development Institute (als.net)
– Project MinE (projectmine.com)
– ClinicalTrials.gov for ongoing studies

Related conditions

Primary Lateral Sclerosis – affects only upper motor neurons, progresses more slowly than ALS.

Progressive Muscular Atrophy – affects only lower motor neurons, may be an ALS variant.

Frontotemporal Dementia – shares genetic causes with some ALS cases, particularly C9orf72 mutations.

Spinal Muscular Atrophy – another motor neuron disease, but typically genetic and presents differently.

Multiple Sclerosis – can cause similar symptoms but follows different disease course and affects different nervous system parts.

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, UpToDate, relevant ALS Association guidelines. This article is for informational purposes only and does not constitute medical advice. Content licensed under CC BY 4.0.

Licensed under CC BY 4.0. Free to share with attribution to GMJ News.

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, EULAR/ACR guidelines. Schema.org MedicalCondition structured data included.